[ad_1]
Shares of Novavax exploded on Friday after the company said end-phase testing showed its coronavirus vaccine to be 96.4% effective against the original viral strain causing Covid-19.
X
The two-dose regimen prevented 100% of severe cases of Covid, including hospitalization and death, in the UK study. Novavax (NVAX) also reported the results of the mid-term tests in South Africa. There, his vaccine was 55.4% effective against infection in HIV-negative participants. A strain in South Africa has been more difficult to target for vaccines.
Thursday marked “a year since the World Health Organization officially declared the Covid-19 pandemic, and with this data in hand, we are even more motivated to advance our vaccine as a potential weapon in the world. fight to end the suffering caused by Covid-19, ”said Stanley Erck, CEO of Novavax, in a written statement.
On the stock market today, Novavax stock jumped 8.1% to 202.77.
Increase in Novavax stocks during phase 3 test
The UK study recruited more than 15,000 participants aged 18 to 84. Of these, 27% were volunteers over 65.
In addition to being 96.4% protective against the original strain, the vaccine has also blocked 86.3% of Covid cases due to a mutated strain first identified in the UK. Briton is considered more contagious, although it has not largely escaped vaccines.
Among people aged 65 and over, there were 10 cases of Covid-19 and 90% of these occurred in the placebo group.
The study in South Africa recruited 2,665 healthy adults. A small group of 240 people included medically stable HIV-positive adults. Overall, the drug was 48.6% effective against predominantly variant strains, Novavax said. The HIV negative participants saw an effectiveness of 55.4%.
The actions continue their rampage
Novavax’s stock has been unleashed as hopes soar for its coronavirus vaccine.
Numerically, the efficiency of 96.4% is better than the results Pfizer (PFE), Modern (ARNM) and Johnson & johnson (JNJ). All three have licensed vaccines in the United States. In final phase testing, their vaccines were 95%, 94.1% and 66% effective against the virus, respectively. J & J’s vaccine is the only single dose medicine in the pack.
New analysis in Israel earlier this week suggested Pfizer BioNTech The Covid vaccine in partnership with (BNTX) could be 97% effective two weeks after the second dose.
It is important to note that experts generally do not recommend making comparisons between studies due to differences in patient populations and goals. At this point, Novavax and J&J were testing their vaccines at a time when variants were emerging. Pfizer and Moderna did not note the changes in their press releases at the time.
The rise of the Novavax share this year is reflected in its best possible relative strength rating of 99. The RS rating pits the performance of a stock over 12 months against that of all other stocks. This places Novavax in the top 1% of all inventory on this measure, according to IBD Digital.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Catapults of biotechnology stocks after the success of the drug Covid, partner of GSK
Drug stock jumps on evidence to suggest its Covid vaccine is almost 100% effective
Options trading: how to start using options, how to manage risk
Join IBD Live for action ideas each morning before opening
Best Growth Stocks to Buy and Watch: See IBD Stock Lists Updates
[ad_2]
Source link